more news is due in april... head to head with fluzone. note today's pr and the earnings conference call highlighted that neuraminidase inhibition is a big focus and that the co is in ongoing discussions with the FDA as to how to do a phase III.
flu is flu and pandemic becomes seasonal... next year all the seasonal shots will have AH1N1 in them. i guess this is what nvax is talking to the fda about... how to design a phase III that meets seasonal and pandemic standards.
News 
Market Data 
Discover 
